FGFR1 and glioblastoma: Based on all the previous preclinical and clinical data, the main objective of our study is to evaluate the radiosensitizing potential of pemigatinib, which specifically targets FGFR1, for differentiated glioblastoma cells and GSCs, when used in conjunction with radiotherapy both in vitro and in vivo.